Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J3L-MC-EZEB Phase 2 Study of LY3819469 in Adults with Elevated Lipoprotein(a)
2022-501426-38-00Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing LY3819469 with Placebo (2 arms). Primary endpoint: Percent change from baseline in time-averaged Lp(a) over Days 60-180. Started Jan 2023; status: completed.
02
Drugs
lepodisiran
03
Conditions
lipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on 2022-501426-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501426-38-00.